Unknown PHASE2 INTERVENTIONAL 2-arm NCT03451760

Feru-guard for Behavioral Symptoms in Dementia

Feru-guard (Ferulic Acid and Angelica Archangelica Extract) for Behavioral Symptoms in Dementia

Sponsor: Glovia Co., Ltd.

Conditions Behavioral and Psychiatric Symptoms of Dementia

Interventions Feru-guard 100M Feru-guard 100M Placebo

Updated 7 times since 2018 Last updated: Aug 1, 2018 Started: Sep 30, 2018 Primary completion: Dec 31, 2019 Completion: Dec 31, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03451760, this PHASE2 trial focuses on Behavioral and Psychiatric Symptoms of Dementia and remains ongoing. Sponsored by Glovia Co., Ltd., it has been updated 7 times since 2018, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Sep 2020 — Jan 2021 [monthly]

Unknown Status PHASE2

Status: Not Yet Recruiting → Unknown Status
Sep 2018 — Sep 2020 [monthly]

Not Yet Recruiting PHASE2

▶ Show 2 earlier versions

Jun 2018 — Sep 2018 [monthly]

Not Yet Recruiting PHASE2
Mar 2018 — Jun 2018 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Glovia Co., Ltd.
Oregon Health and Science University

Data source: Glovia Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.